Table 1 Baseline demographics and disease characteristics of the total population (N=44)

From: Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

Characteristics

N =44

Age, years, median (range)

65 (52–77)

ECOG performance status

0–1

26 (82)

2

8 (18)

Histological type

Endometrioid

28 (64)

Serous

11 (25)

Othera

5 (11)

Histological grade

1

9 (20)

2

16 (36)

3

17 (39)

Unknown

2 (5)

Metastatic sites

Abdomen/pelvis

25 (57)

Lung

23 (52)

Lymph nodes

20 (45)

Liver

15 (34)

Treatment-free interval

<3 Months

16 (36)

3–6 Months

12 (28)

>6 Months

16 (36)

Previous chemotherapy

44 (100)

1 Line

29 (66)

2 Lines

15 (34)

  1. Abbreviation: ECOG=Eastern Cooperative Oncology Group.
  2. Note: Unless otherwise noted, all data are presented as n (%).
  3. aIncludes three clear-cell carcinomas, one mixed Müllerian tumour, and one undifferentiated tumour.
Back to article page